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Abstract 
Background/Aims : External pilot trials are recommended for testing the feasibility 
of main or confirmatory  trials. However, there is little evidence that progress in 
external pilot trials actually predicts randomisation and attrition rates in the main trial. 
To assess the use of external pilot trials in trial design we compared randomisation 
and attrition rates in publicly funded RCTs with rates in their pilots.  
Methods: RCTs for which there was an external pilot trial were identified from 
reports published between 2004 and 2013 in the Health Technology Assessment 
Journal. Data were extracted from published papers, protocols and reports. Bland-
Altman plots and descriptive statistics were used to investigate the agreement of 
randomisation and attrition rates between the full and external pilot trials.  
Results: Of 561 reports 41 were RCTs with pilot trials and 16 met criteria for a pilot 
trial with sufficient data. Mean attrition and randomisation rates were 21.1% and 
50.4% respectively in the pilot trials and 16.8 % and 65.2% in the main. There was 
minimal bias in the pilot trial when predicting the main trial attrition and 
randomisation rate.  However, the variation was large: the mean difference in the 
attrition rate between the pilot and main trial was -4.4% with limits of agreement of    
-37.1% to 28.2%. Limits of agreement for randomisation rates were -47.8% to 77.5%. 
Conclusions: Results from external pilot trials to estimate randomisation and attrition 
rates should be used with caution as comparison of the difference in the rates between 
pilots and their associated full trial demonstrates high variability. We suggest using 
internal pilot trials wherever appropriate.  
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2 Background:  
In the United Kingdom 2014/2015, the National Institute for Health Research in 
England invested £237.6 million to assess new health technologies1 .  A large 
proportion of this research has been Randomised Controlled Trials (RCTs)  
 
A common problem with publicly funded RCTs is that the recruitment in the trial is 
not as good as anticipated with many trials failing to reach their target sample size. A 
review of a cohort of trials funded by the UK Medical Research Council and the 
Health Technology Assessment  Programme  between 2002 and 2008 demonstrated 
that  of  73  funded  studies  recruiting 55% (40/73) of the trials achieved their 
original patient recruitment target; 16/73 (22%) achieved <80% of their original target 
and 45% (33/73) were awarded an extension.2  
 
One way to mitigate the risks of conducting a large clinical trial is to undertake small 
preliminary or pilot trials first.  This may help facilitate the design of the main trial by 
enabling an estimate assessment of the recruitment and attrition rates for the trial.  A 
recent review of Health Technology Assessment funded trials found that the average 
attrition rate was 11% whilst the average proportion of randomized to eligible patients 
was 70% .3 Accurate estimates of both these rates are important a priori for the design 
of future studies. 
 
It should be highlighted though that pilot studies are not just designed to inform on 
recruitment.  They can also give confidence that a clinically meaningful effect is 
likely to be observed4  and inform sample size calculations.5,6 .  When they are 
successful they can provide sufficient confidence that a larger trial can be 
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conducted.7,8   Even when the results are not as expected the experiences from the 
trial can still be useful. 9,10  
 
The sample size calculation is an essential step in the design of a randomised 
controlled trial (RCT). 11,12 An important aspect of a sample size calculation is that it 
provides the researcher with an estimate of the number of evaluable participants 
required in the dataset at the end of the study in order to investigate the study 
hypothesis with the required level of power for a given level of statistical 
significance.  
 
An important consideration when estimating the evaluable sample size and designing 
the trial are the facts that not all patients who are approached will consent to being in 
the trial and of those who consent not all will complete the trial and have evaluable 
outcome data and information for the statistical analysis. Participants with non 
evaluable data are defined as the participants lost during the course of the study due 
withdrawal or drop-out. Participants can withdraw from a study for any number of 
reasons such as discontinued participation in treatment, missing study visits at 
outcome measure time points or non-completion of study data collection forms.13 To 
assist in the design of a RCT therefore, we need to have estimates of the proportion of 
eligible participants who will enter the study and are randomised as well as the 
proportion of randomised participants who will have evaluable data. The proportion 
randomised and the proportion of patients with evaluable data can be estimated from a 
pilot trial.   
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To account for the attrition (also referred to as withdrawal or dropout) of participants 
during the trial, the calculated sample size must be increased to deliver a sufficient 
number of evaluable participants at the end of the trial when the outcome data are 
analysed to ensure the appropriate power. Hence, if the number of withdrawals is 
underestimated the trial will not have the appropriate evaluable sample size and 
necessary power.  Conversely overestimating the number of withdrawals could lead to 
over recruitment in the trial with more patients potentially exposed to inferior 
treatments. This can occur for example where the follow-up phase is long (for 
example 2 years)  in relation to the recruitment phase and recruitment finishes before 
the extent of the lower than anticipated attrition is known.  
 
Once we have calculated the number of participants that we need to randomise in 
order to have the required number of evaluable participants we need to have some 
estimate of the proportion of eligible patients who will be randomised.  This is 
required for planning purposes to ascertain the recruitment period for the trial. 
 
Using a pilot trial to estimate parameters for the main RCT has a number of 
advantages over using data from published literature. The main advantage is that the 
pilot trial can be designed to be a miniature version of the main trial ± for example in 
the same trial population with similar inclusion and exclusion criteria. In contrast, 
previously reported trials may differ from the trial being planned in ways which 
impact on the accuracy of the estimates. 
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Eldridge proposes that a pilot study should be considered to be a subtype of feasibility 
study with both feasibility and pilot studies aimed at answering whether and how 
something can be done, a pilot study being designed specifically as the full study but 
on a smaller scale. 14. Guidance on good reporting of pilot and feasibility trials has 
been published. 15  
 
The National Institute for Health Research define a pilot study as a miniature version 
of the main study to determine whether the components of the main study can work 
together.16 Their guidance distinguishes between internal and external pilots, the 
former being the first phase of a substantive study which contributes data to the main 
analysis. The latter are undertaken prior to the substantive study with the data being 
analysed separately from the main study.16 
 
Lancaster has outlined the possible objectives that an external pilot study can achieve 
including: testing the integrity of the study protocol; testing the randomisation 
procedure; finding the rates of recruitment and consent; assessing the acceptability of 
the intervention and identifying the most appropriate primary outcome measure.17  
 
The aims of this paper are to describe and compare the attrition rates and the rates of 
eligible to randomised patients of external pilot trials with those of their respective 
main RCTs in order to ascertain whether external pilot trials usefully predict these 
attributes in the main trial.  
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3 Method: 
3.1 Trial Identification: 
To fulfil the aims of this study an audit of RCTs with pilot trials was carried out in 
two phases. An initial set of RCTs published between 2004 and 2013 were collected 
from reports published online in the Health Technology Assessment Journal.18 The 
criteria for inclusion of trials in this first stage of the audit were: single or multi-centre 
RCTs, fully or partially randomised main trials and trials reporting early termination. 
The following were excluded: cluster randomised trials, trials that used adaptive 
designs, trials of Influenza (because they recruit very quickly over a short period), 
external pilot trials.  Cluster trials were excluded as the unit of randomization is 
different from that of individually randomised trials. In a cluster trial one may not be 
obtaining individual consent from patients and what is of interest in cluster trials is 
how many eligible clusters when approached agree to be randomized and what is the 
attrition of the clusters. 
 
In this initial audit, information was collected about whether or not the RCT had a 
pilot trial. Trials which had been identified as having a pilot trial then went forward 
into the second phase of the audit. The second phase of the audit assessed each of the 
pilot trials to see whether they matched our definition of a pilot trial and whether they 
were therefore eligible to be entered into our study.  
 
Although there are a number of definitions of pilot studies19-22 we based our definition 
on that of the National Institute for Health Research at the time of the study which is 
that a pilot study is a smaller version of the main study undertaken to test whether the 
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components of the main study can all work together.16  This definition has been 
recommended for use as pilot studies have been found to be poorly reported, in part 
due to variation in definitions and lack of distinct between pilot and feasibility 
studies19 .  To qualify the study for inclusion, in line with this definition, the pilot trial 
had to be a version of the main study run in miniature and include assessment of some 
processes of the main study for example recruitment and randomisation rates and/ or 
outcome measure collection. Pilot studies expressly aimed at assessing factors other 
than recruitment and attrition rates (for example sample size and outcome measures) 
were included if data were available or could be obtained from authors to allow 
assessment of recruitment or attrition rates or both. 
 
3.2 Eligibility Criteria 
Trials were eligible for analysis if they were eligible in the initial phase of the audit 
and had an external pilot trial which conformed to our definition of a pilot trial.  
 
3.3 Data Extraction: 
For the main trials data were extracted by using the individual trial papers, trial 
protocols and Health Technology Assessment Journal reports. For the pilot trials 
where published papers were available these were used to extract the required data. 
Some information was also gained by consulting the main trial study protocols. In 
some circumstances not all of the required information was available from these 
sources. There was no published paper for most of the pilot trials so limited 
information was available in some cases. For trials with missing data the information 
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was requested directly from the corresponding author of the trial report. The data 
extracted were entered and analysed in Microsoft Excel. 
 
Data extracted included: numbers of patients eligible, randomised and available for 
analysis; number of centres in the main trial; reporting of involvement of a Clinical 
Trials Unit in the main trial; length of follow-up period in pilot and main trial. 
 
3.4 Analysis: 
The analysis is mainly descriptive.  Bland-Altman plots were used to test the level of 
agreement and to look at the bias of the results from the pilot trial in predicting the 
main trial outcomes. The primary outcome variables were  
x The attrition rate - derived by dividing the number of withdrawn participants 
(calculated as the number of people retained in the study subtracted from the 
total number randomised) by the number originally randomised. 
x The rate of eligible patients who are randomised - derived by dividing the 
number of patients randomised into the trial by the number originally 
identified as eligible. 
The difference was calculated as pilot minus main trial results. 
 
Secondary exploratory analysis was undertaken to investigate a number of factors 
which could potentially explain the differences in the estimates including number of 
centres, number of participants and involvement of a Clinical Trials Unit. 
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4 Results 
In total 561 reports published in the Health Technology Assessment Journal were 
available from trials completed between 2004 and 2013. From which, 459 of the 
reports were excluded for not being RCTs or for being cluster randomised controlled 
trials leaving 102 RCTs. A further 3 RCTs were excluded from the initial audit in the 
first phase, leaving 99 RCTs. Of these trials 58 trials had no pilot trial. The remaining 
41 studies were reviewed and further studies were excluded as: did not have sufficient 
data (n = 2), was a cluster RCT (n=1), did not conform to our definition of a pilot trial 
i.e. did not include assessment of some processes of the main study for example 
recruitment and randomisation rates and/ or outcome measure collection (n = 17); the 
pilot trial was an internal pilot (n = 5 studies). The studies which did not provide 
sufficient data were excluded after emails were sent, without a sufficient response, to 
the trial investigators requesting the missing information. Sixteen external pilot trials 
were analysed. Figure 1 summarises the flow of the trials throughout the review. 
 
Primarily we were interested in how well the pilot trial attrition rate predicts the 
attrition rate in the main trial. The mean attrition rate in the pilot trials was 21.1% 
(standard deviation  = 16.0%) [Median = 23.5%, Interquartile range = 5.9%, 31.9%] 
and the mean attrition rate in the main trials was 16.8% (Standard deviation =11.66%) 
[Median = 10.8%, Interquartile range = 5.8%, 28.0%]. Figure 2 compares the attrition 
rates of the pilot trials with those of the main trials. The difference between the two 
rates is plotted on the vertical axis against the mean attrition rate for the two trials 
(main and pilot) on the horizontal axis. This graph shows minimal bias in the pilot 
trial when predicting the main trial attrition rate, the average difference in the attrition 
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rate between the pilot and the main trial is -4.4%. Thus on average the attrition 
difference (depicted by the red line) is 4.4% percentage points less in the main trial 
compared to the pilot trial. However, the standard deviation of the differences is large 
16.3%. The 95% limits of agreement are -37.1% to 28.2%. 
 
To investigate the predictability of the pilot studies for the main trial retention rates a 
regression analysis was undertaken.  With just the mean pilot retention in the model 
for a mean pilot retention rate of 21.1% the model would predict the main trial 
retention to be 16.7% - 4.4% lower than in the pilot. The standard deviation of the 
difference from the same model is 16.2%.  These results are consistent with the 
results above.  If in the same model we had also the pilot sample size the mean 
predicted retention (for an average size pilot trial of 62 subjects) is 16.6%.  The mean 
difference is thus similar to before at -4.5%.  However, the standard deviation of this 
difference is reduced to 13%.  The implication of this result is that the bigger the pilot 
study the less variation there would be between the observed retention rates in the 
pilot and main trials. 
 
Figure 3 compares the rates of patients who were eligible to be in the trials that were 
randomised for the pilot trial and main trials.  For the limited data in the analysis the 
graph shows minimal bias 
 
The mean percentage of eligible patients that were randomised for pilot trials was 
50.4% (Standard deviation = 22.4%) [Median = 48.9%, Interquartile range = (30.3%, 
61.3%)] and for main trials the average was 65.2% (Standard deviation = 23.2%) 
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[Median = 60.9%, Interquartile range = (45.7%, 92.5%)]. The mean of the differences 
between the pilot and the main trial is 14.9.  This shows that the bias for pilot trials 
predicting the main trial rate of eligible patients who are randomised is small. 
However, again the standard deviation of this is large, 31.3%. The limits of agreement 
are -47.8% to 77.5% implying that the pilot could underestimate the rate of eligible 
patients randomised patients by as much as 77.5% and overestimate it by as much as 
47.8%. 
 
We repeated the regression analysis to see if the size of the pilot improved 
predictability of the main trials randomisation rates.  With just the pilot randomisation 
rates in the model for a mean pilot rate of 50.6% the prediction was that the mean 
randomisation rate in the main trial would be 65.2%.  This gives an average 
difference of 14.6% which is comparable to before.  The standard deviation for this 
difference is a little bigger than before at 35.9%.  Having the pilot sample size in the 
model reduces the mean predicted randomisation rate to 38.1% for the main trial and 
increases the standard deviation to 40.0%.  On the face of it this is a wide change in 
the prediction but in actuality it is confirming that that the pilot trials in our study did 
not predict the randomisation rates in the main trials. 
 
The trial that gave the largest difference (67.1%) between the rates from the pilot and 
the main trial noted in the Health Technology Assessment Journal report that there 
were fewer eligible patients presenting than projected from the pilot trial and trial 
staff took action to maximise the recruitment.  
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When making any assessment it is not just the point estimate which is of importance 
but also the accompanying confidence interval which gives a range of plausible 
responses for the true effect.  When we investigated the confidence intervals for the 
drop out we found that for 10 of the 13 trials the dropout rates in the main trials were 
contained within the 95% confidence intervals for the pilot estimate dropout rates. For 
the 3 where the main trial rates were not within the confidence interval 2 had lower 
dropout rates compared to the pilot and 1 had higher. For the eligible to randomised 
rate of the 7 trials where we had the information only 2 of the main trials had rates 
which fell within the 95% confidence interval for the pilot trial. 
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4.1 Secondary Results 
Table 1 shows the results from a secondary analysis investigating some features of a 
trial which could cause the differences in the attrition rates and the randomisation 
rates between the pilot and the main trials, including number of centres, number of 
participants and involvement of a Clinical Trials Unit in the main trials and stated 
differences in length of follow-up period between the pilot and main trial  
 
For the mean difference between attrition rates a negative value implies that the 
withdrawal rate was less in the main trials than in the pilot trial. For the difference 
between the rate of eligible patients randomised a negative values depicts a situation 
where the conversion of eligible patients into randomised patients was better in the 
pilot trial than in the main trial. 
 
For these secondary results: for attrition a negative value shows that the attrition was 
higher in the pilot than the main trial, for the rate of eligible patients randomised the 
higher the rate the more patients that were eligible were randomised therefore the 
higher the better. A positive value shows a better rate in the main trial than the pilot. 
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The table demonstrates that for trials where it was stated that a Clinical Trials Unit 
was involved the drop out in the main trial was less than that in the pilot and the 
randomisation rate was also greater in the main trial. Where there was no indication 
that a Clinical Trials Unit was involved in the main trial, attrition rates were higher 
and randomisation rates lower in the main trial compared with the pilot. These results 
must be viewed with caution though as no reporting of Clinical Trials Unit 
involvement does not necessarily mean that one was not involved. 
 
5 Discussion 
We found in our investigation that in terms of predicting the proportion of participants 
who withdraw from a trial and the rate of eligible patients that were randomised 
external pilot trials were consistent in terms of the mean difference and provided 
unbiased estimates for these values in the main trial.  However, we also found 
evidence of large variation in the randomisation and attrition rates between pilot trials 
and their associated main trial. 
 
The mean attrition rate in the main trials was 16.8% compared with 11% in a recent 
review of Health Technology Assessment funded trials (with and without pilot trials). 
The mean randomisation rate in main trials in this study was 65.8% compared with 
70% in the recent review.  
 
There is a perception in the clinical research community that external pilot studies are 
likely to overestimate recruitment rates. Avery identified the cause of this as pilot 
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centres being chosen because of where co-applicants work or have previous 
collaborations or through selecting safe or enthusiastic centres. Their concern was that 
recruitment rates in pilot studies may be difficult to replicate when widening out to 
include more centres in the full study.23  It is interesting that this study demonstrated 
no consistent overestimate of recruitment rates by the external pilot studies, neither 
did it find consistent underestimation of attrition rates.  
 
The results need to be interpreted with caution as there were outliers in the analysis 
which contributed to wide limits of agreement. Consideration also needs to be given 
to the fact that a study team is only likely to proceed to a main trial if the pilot trial 
gives sufficient confidence that the main trial is plausible.  Pilot trials which do not 
provide sufficient confidence in the value of proceeding, for example where 
randomisation or recruitment rates are very low or attrition is very high, are less likely 
to progress to a main trial. As only pilot studies which progressed to a main study 
have been included here there may be some bias in studies available for assessment..   
 
A limitation to this study is that the differences in the data between the pilot and the 
full trial could have been due to remedial action taken in the full trial to address 
problems with recruitment and attrition identified in the pilot e.g. changes to 
recruitment processes. Such changes would have been intended to improve the 
randomisation and attrition rates from the pilot to the full trial. This could explain the 
finding that involving a Clinical Trials Unit  in the main trial was associated with an 
increase in randomisation rates and reduction in drop-out rates in the main trial 
compared with the pilot. However, there was insufficient information available to 
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assess whether this was the case or whether differences were due to non-systematic 
factors. 
 
It is well established that a significant proportion of trials fail to meet their 
recruitment targets24 and this has led to increased interest in undertaking external pilot 
trials. However, external pilot trials are not without cost in terms of time, effort, 
money and delay in delivering the definitive results about whether a potentially 
valuable health intervention is effective or not.  
 
External pilot trials have demonstrated clear value where there are many unknown 
factors including whether the intervention or outcome measures are acceptable to 
participants and where uncertainties exist around the implementation of the 
intervention.7,25-28  In such cases an external pilot trial is likely to be more appropriate 
than an internal pilot. However, based on the findings of this study we would 
recommend that where the key unknown factors are randomisation and retention rates 
alone, investigators should consider using an internal pilot rather than an external 
pilot. An internal pilot as the first part of the main trial has a number of advantages 
over an external pilot.29  Undertaking an external pilot trial can delay the main study 
by three to four years by the time the pilot study has completed, reported and further 
funding has been applied for. In contrast, if randomisation and attrition rates within an 
internal pilot are on target and progression review is included within the trial 
protocol8,30 progression to the full trial can be rapid. The use of internal pilot trials is 
reported as having the potential to optimise trial design and recommendations have 
been produced on setting progression criteria to inform the decision to continue to the 
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full study.  Avery suggests that rather than employing dichotomous stop/go criteria, 
investigators should consider a traffic light red/amber/ green system which identifies 
the level of risk to proceeding.23 In addition data from the internal pilot is used in the 
main analysis which is not the case for external pilots and is therefore a more efficient 
use of data. This also means an internal pilot requires fewer total participants than 
using an external pilot which  may be crucial where the availability of eligible 
patients is limited for example in rare conditions. Recognition of the importance of 
using the pilot data in the final analysis has lead to the development of a checklist to 
guide investigators about when this can be done appropriately.29  
 
It should be noted that the results in the paper are based on a relatively small sample 
size.  After exclusion of ineligible studies and those for which insufficient data was 
available only 16 trials were included for analysis. Repeating this audit with more 
cases may produce more accurate estimates. There may be value in repeating this 
including subsequent reports. 
 
6 Conclusions 
This study demonstrates evidence of large variation in the randomisation and attrition 
rates between external pilot trials and their associated main trial in the published 
literature. We recommend that, in circumstances where the intervention is developed 
and stable and the appropriate outcome measures are established, i.e. where the main 
unknowns are recruitment rate and attrition, an internal pilot should be considered 
over an external pilot. Even if an external pilot had been undertaken we would also 
20 
 
recommend an internal pilot as the early phase of the main trial. The focus of the 
internal pilot would be to monitor randomisation and attrition rates within the early 
stages and then to modify processes to facilitate recruitment and retention or increase 
the numbers of participants recruited if necessary.  
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Figure 1: Flowchart of search process for the reviews of trial reports published in the 
Health Technology Assessment Journal between 2004 and 2013 for the inclusion of 
trials in the study 
 
561 Monographs title 
and abstracts 
screened 
102 RCTs Screened 
459 reports excluded: 
reports are not RCTs or 
are of cluster randomised 
RCTs 
99 RCTs analysed 
3 RCTs excluded: 
x 1 pilot study 
x 2 influenza 
vaccination trials 
58 RCTs excluded for 
having no pilot trial  
41 Pilot trials screened 
16 External Pilot trials 
analysed 
A further 25 trials 
excluded: 
x 17 which had no pilot 
x 1 cluster RCT 
x 5 trials with Internal 
pilot study 
x 2 with insufficient 
data 
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Figure 2: Bland-Altman plot looking at the difference in attrition rates between the 
pilot and main trial 
 
 
Figure 3: Bland-Altman plot looking at the difference in percentage of eligible 
patients randomised between the pilot and main trial 
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Table 1: Investigating potential factors which may affect the difference in attrition 
rate and of the rate eligible patients who were randomised  between the pilot and main 
trials 
Characteristic Mean % difference 
between the attrition rates 
(Standard deviation) [n] 
Mean % difference between 
the randomised/eligible 
(Standard deviation =) [n] 
Greater than 5x 
more centres in the 
main 
Yes -4.3 (17.6) [8] 20.5 (65.9) [2] 
No -0.18 (14.6) [4] 10.3 (21.2) [4] 
Stated involvement 
of a Trials Unit in 
the main trial 
Yes -7.8 (16.0) [9] 25.6(29.5) [5] 
No 3.3 (16.4) [4] -12.0 (20.9) [2] 
Change in the 
length of follow-up 
in the main trial 
Yes -5.7 (17.4) [11] 19.3 (31.9) [6] 
No 2.8 (6.6) [2] -11.5(N/A) [1] 
Greater than 10x 
more patients in 
the main trial 
Yes -12.3 (17.8) [7] 33.6 (29.4) [3] 
No 4.8 (8.4) [6] 0.77 (27.8) [4] 
 
